Cyclic Guanosine Monophosphate and Risk of Incident Heart Failure and Other Cardiovascular Events: the ARIC Study

BACKGROUND: Cyclic guanosine monophosphate (cGMP) is a second messenger regulated through natriuretic peptide and nitric oxide pathways. Stimulation of cGMP signaling is a potential therapeutic strategy for heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular dis...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Am Heart Assoc
Autors principals: Zhao, Di, Guallar, Eliseo, Vaidya, Dhananjay, Ndumele, Chiadi E., Ouyang, Pamela, Post, Wendy S., Lima, Joao A., Ying, Wendy, Kass, David A., Hoogeveen, Ron C., Shah, Sanjiv J., Subramanya, Vinita, Michos, Erin D.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7033823/
https://ncbi.nlm.nih.gov/pubmed/31928156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.119.013966
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars